Cluster headache: present and future therapy

Neurol Sci. 2017 May;38(Suppl 1):45-50. doi: 10.1007/s10072-017-2924-7.

Abstract

Cluster headache is characterized by severe, unilateral headache attacks of orbital, supraorbital or temporal pain lasting 15-180 min accompanied by ipsilateral lacrimation, rhinorrhea and other cranial autonomic manifestations. Cluster headache attacks need fast-acting abortive agents because the pain peaks very quickly; sumatriptan injection is the gold standard acute treatment. First-line preventative drugs include verapamil and carbolithium. Other drugs demonstrated effective in open trials include topiramate, valproic acid, gabapentin and others. Steroids are very effective; local injection in the occipital area is also effective but its prolonged use needs caution. Monoclonal antibodies against calcitonin gene-related peptide are under investigation as prophylactic agents in both episodic and chronic cluster headache. A number of neurostimulation procedures including occipital nerve stimulation, vagus nerve stimulation, sphenopalatine ganglion stimulation and the more invasive hypothalamic stimulation are employed in chronic intractable cluster headache.

Keywords: CGRP; Cluster headache; Drugs; Neurostimulation; Treatment.

Publication types

  • Review

MeSH terms

  • Animals
  • Calcitonin Gene-Related Peptide / antagonists & inhibitors*
  • Calcitonin Gene-Related Peptide / metabolism
  • Cluster Headache / diagnosis
  • Cluster Headache / metabolism
  • Cluster Headache / therapy*
  • Electric Stimulation Therapy / methods
  • Electric Stimulation Therapy / trends*
  • Forecasting
  • Humans
  • Sumatriptan / administration & dosage
  • Vagus Nerve Stimulation / methods
  • Vagus Nerve Stimulation / trends
  • Verapamil / administration & dosage

Substances

  • CALCA protein, human
  • Sumatriptan
  • Verapamil
  • Calcitonin Gene-Related Peptide